WO2005105125A1 - 骨粗鬆症予防または治療剤 - Google Patents
骨粗鬆症予防または治療剤 Download PDFInfo
- Publication number
- WO2005105125A1 WO2005105125A1 PCT/JP2005/003197 JP2005003197W WO2005105125A1 WO 2005105125 A1 WO2005105125 A1 WO 2005105125A1 JP 2005003197 W JP2005003197 W JP 2005003197W WO 2005105125 A1 WO2005105125 A1 WO 2005105125A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kudzu
- water
- agent
- preventing
- osteoporosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- the present invention relates to a water-soluble fraction of roots or stems of kudzu (Kuzura, a plant belonging to the genus Pueraria), which is useful as an agent for preventing or treating osteoporosis, and a pharmaceutical, food or drink containing the same.
- Therapeutic agents for osteoporosis include calcium preparations, active vitamin D, anabolic hormones, and bone resorption inhibitors. The higher the efficacy, the narrower the difference between the safe and toxic areas, making it difficult to adjust the dosage. In addition, there are many issues with long-term safety
- isoflavones which are rich in legumes, have a preventive and ameliorating effect on osteoporosis.
- isoflavones such as daizenin and genistein have been identified as the main effects and reported as functional food materials (See Patent Document 1).
- Kudzu Korean, Pueraria spp.
- Udzu Pueraria spp.
- the food is unused except for the root starch.
- Kudzu is also a legume, and is presumed to have a high isoflavone content.
- Patent Document 2 JP-A-9-309902
- Patent Document 2 JP 2003-95971 A
- the present invention is different from currently used preventive or therapeutic agents for osteoporosis and synthetic hormone preparations and has few side effects.
- the aim is to provide drugs, drugs, and foods and beverages that are effective in preventing and improving osteoporosis.
- the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that bones excellent in water-soluble extracts of the roots, stems, and flowers of Kudzu, which has long been used as a Chinese herbal medicine in Japan.
- the present inventors have found out the effect of suppressing absorption and have further studied and completed the present invention.
- the present invention relates to a preventive or therapeutic agent for osteoporosis, which comprises a water-soluble extract of roots, stems and flowers of kudzu as an active ingredient.
- the present invention has a strong resistance to wasteland, has a strong growth potential, and is the most prolific plant resource in the mid-latitude temperate zone of the world. A certain waste can be used effectively.
- the water-soluble fraction of the present invention which is extracted from the roots, stems, or flowers of Kudzu, has an effect of inhibiting bone resorption, and is useful as a food and drink or a pharmaceutical product that is effective in preventing and improving climacteric disorders such as osteoporosis.
- FIG. 1 is a view showing the results of HPLC analysis showing the isoflavone content of each sample of root, perennial stem, annual stem, and leaf in Example 2.
- FIG. 2 is a diagram showing the results of HPLC analysis showing the isoflavone content of a flower extraction powder in Example 2.
- FIG. 4 Graph showing the results of examining the inhibitory effect of perennial stem ethanol extract of kudzu on bone resorption in ovariectomized osteoporosis model animals by measuring changes in bone metabolic markers Pyr and Dpyr. It is.
- Fig.5 The inhibitory effect of puerarin, which is abundant in the root and stem extracts of Kudzu, on bone resorption in ovariectomized osteoporosis model animals is determined by measuring changes in bone metabolic markers Pyr and Dpyr. It is a graph showing the result of verification
- the present invention was conceived assuming that it would be possible to use the isoflavones in the kudzu ingredient as an effective food material if the effects of preventing or treating osteoporosis of the isoflavones were clarified, and if an efficient method for preparing the active ingredient was established, the active ingredient could be used.
- the active ingredient can be prepared from other tissues, such as spontaneous stems that are left undisposed and discarded, for example, from the roots, leaves, annual stems, perennial stems, and flowers of kudzu.
- the water-soluble fraction was extracted, and the effect of inhibiting bone metabolism was examined. It was found that the extract of root, stem and stem had excellent osteoporosis preventive and therapeutic effects.
- the fractionation and purification were carried out, and it was clarified that the active substance was S isoflavones, particularly puerarin, a component specific to kudzu, and based on this finding, the present invention was completed.
- the water-soluble fraction of the present invention is produced by cutting or pulverizing raw or dried vine or stem or flower of kudzu, or extracting them with a suitable solvent.
- the extraction solvent include hydrophilic solvents such as water, ethanol, methanol propanol, acetate, and tetrahydrofuran. These may be used alone or in combination of two or more. In particular, when water and ethanol are used alone, a mixed solvent system in which these are mixed at an arbitrary ratio is preferable from the viewpoint of safety.
- the extraction conditions can be arbitrarily determined. For example, extraction can be performed simply by immersing the crushed waste of stalks in an extraction solvent of about 3 to 5 times at room temperature or under heating for 15 hours.
- the extract may be used as it is after removing solids by filtration or centrifugation.
- Force Extraction solvent is distilled off by a known appropriate method, and it may be used as an extract or dried.
- Kudzu-derived starch is a widely known food material. Its production involves adding water to the roots of kudzu, refining the starch by repeating the operations of suspension, sedimentation and separation. During this process, it is also possible to produce the bleached water as an extract.
- kudzu is a soybean plant and isoflavones.
- the present inventors have confirmed that 10 to 50% by weight of the water-soluble fraction is isoflavones.
- the composition of isoflavones is characterized by the presence of daizin and genistin, which are also contained in soybeans.
- Puellarin a peculiar component of kudzu, is present in a weight ratio of 30% to 90%. There is.
- the water-soluble fraction of the present invention having an effect of preventing and treating osteoporosis can be administered in a wide range of volumes, and is usually 0.1 to 0.1 mg, preferably 0.1 to 1000 mg / kg body weight, in terms of solid extract. Is between 5 mg and 50 mg.
- the dose is appropriately determined in consideration of sex, age, body weight, etc. of the substance to be administered.
- Foods and drinks for preventing or treating osteoporosis characterized by containing a water-soluble fraction of kudzu of the present invention as an active ingredient include drinks such as juice and health tea, milk drinks, lactic acid drinks, and coffee.
- drinks such as juice and health tea, milk drinks, lactic acid drinks, and coffee.
- Various forms such as beverages, yogurt, jelly, gum, candy, ice, food, granules, capsules, confectionery such as tablet confectionery, health foods and the like can be mentioned. The amount depends on the form of the preparation and the expected degree of osteoporosis prevention or treatment.
- a concentration at which the taste of the material itself does not adversely affect the food it is appropriate to add 0.01 to 10.0% by weight, preferably 0.1 to 5.0% by weight. However, it is not limited to this range if there is no problem with the taste of the food. Further, a lubricant, an emulsifier, a suspending agent, an antioxidant, a sweetening agent, a flavoring agent, and the like can be added according to a standard method. Next, the present invention will be described in more detail with reference to Examples and Test Examples. However, the present invention is not limited to these.
- Example 1 Ethanol-extracted powder of kudzu root and perennial stem of [Preparation Example 1], 19.5% of ethanol-extracted powder of annual stem and leaf prepared in the same manner as in Example 1, 99.5% of Example 1 Extracted powders of roots, perennial stems, annual stems and leaves similarly prepared by replacing ethanol with water were each dissolved in 70% ethanol and filtered, and the resulting solution was subjected to HPLC analysis under the following conditions. Figure 1 shows the results. Although it was below the roots, perennial stems also contained large amounts of isoflavones, which helped.
- A: B 100: 0 ⁇ 15: 75 (0-60min)
- Osteoporosis model mice can be produced by removing the ovaries of female ddy mice 10 weeks or older (Endocrinology, vol. 140, pagel893-1900 (1999)). In addition, a sham mouse was prepared as a control.
- pyridinoline pyridinoline, Pyr
- Dpyr deoxypyridinoline
- the ethanol extract of kudzu root described in Example 1 was dissolved in distilled water.
- the mice were orally administered once daily at a dose of 50 mg / kg body weight for 2 weeks using an oral probe for mice.
- As a diet a general mouse sample was freely taken. The urine of those mice was collected daily and the amount of Pyr and Dpyr excreted in the urine was determined.
- Example 4 An osteoporosis model mouse was prepared by the method shown in [Pharmacological Test Example 1]. In other words, ovariectomy was performed on the 98th day of birth, and after breeding for 3 weeks, urinary Pyr and Dpyr were measured for 3 weeks. After confirming that urinary excretion of Pyr and Dpyr due to ovariectomy was enhanced, that is, the symptoms of osteoporosis appeared, ethanol extract of perennial stem of kudzu was dissolved in distilled water for 2 consecutive weeks, and mice were Oral sondes were given once daily at a dose of 20 mg / kg, 50 mg / kg body weight for 2 weeks (7 rats in the 20 mgZkg group, 8 rats in the 50 mgZkg group). As for the diet, general mouse samples were freely taken.
- mice The urine of these mice was collected daily and the amount of Pyr and Dpyr excreted in the urine was determined. At the same time, as controls, urinary Pyr and Dpyr were measured in a group of ovariectomized mice orally administered only distilled water (7 mice) and a group of sham-operated mice (7 Sham mice).
- a tea beverage was produced with the composition of the ethanol extract of the perennial stem of the kudzu used in Example 5, 2 g of green tea powder, 0.3 g of sodium ascorbate, 1000 ml of hot water, and the above components.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512727A JP5027502B2 (ja) | 2004-03-04 | 2005-02-25 | 骨粗鬆症予防または治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-060347 | 2004-03-04 | ||
JP2004060347 | 2004-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105125A1 true WO2005105125A1 (ja) | 2005-11-10 |
Family
ID=35241433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003197 WO2005105125A1 (ja) | 2004-03-04 | 2005-02-25 | 骨粗鬆症予防または治療剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5027502B2 (ja) |
WO (1) | WO2005105125A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006011245A1 (ja) * | 2004-07-26 | 2008-05-01 | 株式会社東洋新薬 | 体脂肪低減剤 |
JP2010215607A (ja) * | 2009-02-17 | 2010-09-30 | Naraken Chusho Kigyo Sien Center | 骨粗鬆症予防・治療剤および破骨細胞分化抑制剤 |
JP2010539086A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのクズのエストロゲン性抽出物およびその使用 |
CN107303006A (zh) * | 2016-04-25 | 2017-10-31 | 株式会社Lg生活健康 | 改善更年期症状或骨质疏松症的组合物 |
JP2020509990A (ja) * | 2017-03-07 | 2020-04-02 | エルジー ハウスホールド アンド ヘルスケア リミテッド | テクトリゲニン−7−0−キシロシルグルコシドを含む女性更年期症状緩和用組成物 |
JP2021106550A (ja) * | 2019-12-27 | 2021-07-29 | 日本クリニック株式会社 | プエラリンを主体とするサプリメント用葛抽出物の製造方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6468318A (en) * | 1987-09-08 | 1989-03-14 | Ota Isan Kk | Prophylactic improver or hepatic function disorder |
JPH11511471A (ja) * | 1995-09-20 | 1999-10-05 | ダシン,フー | 抗中毒性組成物(エタノール消費の効果を軽減するための組成物) |
JP2003095971A (ja) * | 2001-09-27 | 2003-04-03 | National Institute Of Health & Nutrition | 骨粗鬆症治療剤または組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6416709A (en) * | 1987-07-11 | 1989-01-20 | Ichimaru Pharcos Inc | Cosmetic containing extract of puerariae radix blended therein |
-
2005
- 2005-02-25 JP JP2006512727A patent/JP5027502B2/ja not_active Expired - Fee Related
- 2005-02-25 WO PCT/JP2005/003197 patent/WO2005105125A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6468318A (en) * | 1987-09-08 | 1989-03-14 | Ota Isan Kk | Prophylactic improver or hepatic function disorder |
JPH11511471A (ja) * | 1995-09-20 | 1999-10-05 | ダシン,フー | 抗中毒性組成物(エタノール消費の効果を軽減するための組成物) |
JP2003095971A (ja) * | 2001-09-27 | 2003-04-03 | National Institute Of Health & Nutrition | 骨粗鬆症治療剤または組成物 |
Non-Patent Citations (3)
Title |
---|
GO K. ET AL: "Hone. Kansetsu Shikkan no Toyo Igakuteki Approach Kotsu Soshosho ni Okeru Hojin. Kenpi Shoho to Shokubutsusei Estrogen.", BONE., vol. 16, no. 6, 2002, pages 543 - 547, XP002993468 * |
KOSUGE T. ET AL: "Kuzu Denpu Sarashieki kara no Isoflavone Yudotai no Kaishu (A Recovery Procedure of Isoflavones from Drain of Kuzu Starch Factory).", JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY., vol. 33, no. 7, 1986, pages 492 - 495, XP002993470 * |
YOSHII M. ET AL: "Kanpo Seizai no Hinshitsu ni Kansaru Kenkyu (Dai 10 Ho) Kakkon Chu no Isoflavone no Doko.", no. 15, 1996, pages 38 - 40, XP002993469 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006011245A1 (ja) * | 2004-07-26 | 2008-05-01 | 株式会社東洋新薬 | 体脂肪低減剤 |
JP4879741B2 (ja) * | 2004-07-26 | 2012-02-22 | 株式会社東洋新薬 | 体脂肪低減剤 |
JP2010539086A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのクズのエストロゲン性抽出物およびその使用 |
JP2010215607A (ja) * | 2009-02-17 | 2010-09-30 | Naraken Chusho Kigyo Sien Center | 骨粗鬆症予防・治療剤および破骨細胞分化抑制剤 |
CN107303006A (zh) * | 2016-04-25 | 2017-10-31 | 株式会社Lg生活健康 | 改善更年期症状或骨质疏松症的组合物 |
JP2020509990A (ja) * | 2017-03-07 | 2020-04-02 | エルジー ハウスホールド アンド ヘルスケア リミテッド | テクトリゲニン−7−0−キシロシルグルコシドを含む女性更年期症状緩和用組成物 |
US11090324B2 (en) | 2017-03-07 | 2021-08-17 | Lg Household & Health Care Ltd. | Composition, for remedying female climacteric syndrome symptoms, comprising tectorigenin 7-O-Xylosylglucoside |
JP7384511B2 (ja) | 2017-03-07 | 2023-11-21 | エルジー ハウスホールド アンド ヘルスケア リミテッド | テクトリゲニン-7-0-キシロシルグルコシドを含む女性更年期症状緩和用組成物 |
JP2021106550A (ja) * | 2019-12-27 | 2021-07-29 | 日本クリニック株式会社 | プエラリンを主体とするサプリメント用葛抽出物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5027502B2 (ja) | 2012-09-19 |
JPWO2005105125A1 (ja) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105125A1 (ja) | 骨粗鬆症予防または治療剤 | |
TW200303726A (en) | Process for producing SDG and foods and drinks containing the same | |
KR102519649B1 (ko) | 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물 | |
JP2016193882A (ja) | 抗老化剤 | |
KR101917363B1 (ko) | 콩 발아배아 추출물을 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학조성물 | |
KR102286429B1 (ko) | 연잎 유래 다당 분획물을 함유하는 골 관련 질환의 개선, 예방 또는 치료용 조성물 | |
JPH10508880A (ja) | 糖尿病用医薬組成物 | |
KR102080410B1 (ko) | 엘더베리 추출물을 유효성분으로 함유하는 남성 갱년기 증후군의 예방, 치료 또는 개선용 조성물 | |
KR101075554B1 (ko) | 돌단풍 추출물 또는 이의 분획물을 유효성분으로 함유하는 폐경기 증후군 예방 및 치료용 조성물 | |
JP6655189B2 (ja) | ブドウ種子抽出物、バレリアン抽出物及びベニバナ種子抽出物を含有する女性更年期症状予防及び改善用食品組成物 | |
KR101851639B1 (ko) | 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물 | |
JP2005047818A (ja) | 健康食品および健康飲料 | |
KR101248378B1 (ko) | 관절염 치료 및 예방용 약학조성물 | |
JP2002363086A (ja) | 骨代謝改善剤及び骨粗鬆症の予防又は治療用飲食物 | |
JP2004323439A (ja) | 血液粘性改善用組成物 | |
KR101018404B1 (ko) | 정금나무 잎 추출물을 유효성분으로 함유하는 콜레스테롤 저하용 조성물 | |
KR101811227B1 (ko) | 구기자, 복분자, 오미자 추출물을 함유한 면역증진, 피로회복, 생리활성 및 해독작용을 위한 조성물 | |
JP2004210675A (ja) | 骨量改善組成物 | |
KR101332531B1 (ko) | 아카시아속 나무 껍질 유래물을 함유하는 소양의 예방 및/또는 치료용 조성물 | |
JP2006257018A (ja) | 抗肥満剤、医薬品および飲食品 | |
KR20050005630A (ko) | 아이쥐에프-1 분비 촉진 활성이 뛰어난 인동 추출물, 이의제조방법 및 용도 | |
KR102408605B1 (ko) | 회화나무, 및 갈근 또는 콩발아배아의 복합추출물을 포함하는 여성 갱년기 질환 및 골 질환 예방 또는 치료용 조성물 | |
KR102448274B1 (ko) | 보골지 추출물의 조다당 분획물을 유효성분으로 함유하는 골질환의 예방, 개선 또는 치료용 조성물 | |
KR101398715B1 (ko) | 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물 | |
KR20110078237A (ko) | 비파 추출물을 함유하는 비만 치료 또는 예방용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512727 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |